{"id":"https://openalex.org/W2280243609","doi":"https://doi.org/10.1200/jco.1993.11.2.360","title":"Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.","display_name":"Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.","publication_year":1993,"publication_date":"1993-02-01","ids":{"openalex":"https://openalex.org/W2280243609","doi":"https://doi.org/10.1200/jco.1993.11.2.360","mag":"2280243609","pmid":"https://pubmed.ncbi.nlm.nih.gov/8426214"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1993.11.2.360","doi":"https://doi.org/10.1200/jco.1993.11.2.360","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1993.11.2.360","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E E Vokes","raw_affiliation_strings":["Department of Medicine, University of Chicago Pritzker School of Medicine, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Chicago Pritzker School of Medicine, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068268371","display_name":"Mark J. Ratain","orcid":"https://orcid.org/0000-0002-0938-4392","observed_orcids":["https://orcid.org/0000-0002-0938-4392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M J Ratain","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052264374","display_name":"Rosemarie Mick","orcid":"https://orcid.org/0009-0004-6215-0538","observed_orcids":["https://orcid.org/0009-0004-6215-0538"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Mick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063954489","display_name":"J M McEvilly","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J M McEvilly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038481817","display_name":"Daniel J. Haraf","orcid":"https://orcid.org/0000-0001-5184-1166","observed_orcids":["https://orcid.org/0000-0001-5184-1166"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Haraf","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021535454","display_name":"Mark F. Kozloff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Kozloff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044802932","display_name":"Victor K. Hamasaki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"V Hamasaki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054855052","display_name":"Ralph R. Weichselbaum","orcid":"https://orcid.org/0000-0002-5643-8939","observed_orcids":["https://orcid.org/0000-0002-5643-8939"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R R Weichselbaum","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109156472","display_name":"W. R. Panje","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W R Panje","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113728950","display_name":"Barry L. Wenig","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B Wenig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":17.8581,"has_fulltext":false,"cited_by_count":69,"citation_normalized_percentile":{"value":0.99716714,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"11","issue":"2","first_page":"360","last_page":"368"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10307","display_name":"Head and Neck Cancer Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2733","display_name":"Otorhinolaryngology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12198","display_name":"Oral health in cancer treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.9240000247955322},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.949999988079071},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9950000047683716},{"id":"https://openalex.org/keywords/leucovorin","display_name":"leucovorin","score":1.0},{"id":"https://openalex.org/keywords/interferon-alpha-2b","display_name":"interferon alfa-2b","score":0.9980000257492065},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7089999914169312},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8550000190734863},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.9750000238418579},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.996999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6880000233650208},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.8019999861717224},{"id":"https://openalex.org/keywords/diabetes-mellitus","display_name":"diabetes mellitus","score":0.9190000295639038},{"id":"https://openalex.org/keywords/age-and-sex-effects","display_name":"age and sex effects","score":0.6069999933242798},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7289999723434448},{"id":"https://openalex.org/keywords/locoregionally-advanced-cancer","display_name":"locoregionally advanced cancer","score":0.8730000257492065}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9311400651931763},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.9172440767288208},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.7118442058563232},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6671302914619446},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6237102150917053},{"id":"https://openalex.org/C2776530083","wikidata":"https://www.wikidata.org/wiki/Q1783924","display_name":"Head and neck cancer","level":3,"score":0.5771839618682861},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5477678775787354},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5286027789115906},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5008063316345215},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4797152876853943},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.45849525928497314},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.4388962984085083},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.41547125577926636},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3543977439403534},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.2438400387763977},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.106749027967453},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.08718055486679077}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002955","descriptor_name":"Leucovorin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006258","descriptor_name":"Head and Neck Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006258","descriptor_name":"Head and Neck Neoplasms","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D006258","descriptor_name":"Head and Neck Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012044","descriptor_name":"Regression Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015999","descriptor_name":"Multivariate Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D048909","descriptor_name":"Diabetes Complications","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1993.11.2.360","doi":"https://doi.org/10.1200/jco.1993.11.2.360","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1993.11.2.360","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:8426214","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8426214","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1404228057","display_name":null,"funder_award_id":"5-P30-CA14599-18","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000865577","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA014599","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":59,"referenced_works":["https://openalex.org/W1495571942","https://openalex.org/W1545320152","https://openalex.org/W1550111394","https://openalex.org/W1583662802","https://openalex.org/W1640401641","https://openalex.org/W1828142674","https://openalex.org/W1845493768","https://openalex.org/W1927227734","https://openalex.org/W1929165921","https://openalex.org/W1966311999","https://openalex.org/W1987862069","https://openalex.org/W1996881328","https://openalex.org/W1998975997","https://openalex.org/W2003202757","https://openalex.org/W2003534255","https://openalex.org/W2005676914","https://openalex.org/W2012717912","https://openalex.org/W2034562813","https://openalex.org/W2041892737","https://openalex.org/W2044310581","https://openalex.org/W2048028926","https://openalex.org/W2048775073","https://openalex.org/W2052333014","https://openalex.org/W2054144111","https://openalex.org/W2065806080","https://openalex.org/W2082102453","https://openalex.org/W2090293084","https://openalex.org/W2100308715","https://openalex.org/W2109261874","https://openalex.org/W2129690877","https://openalex.org/W2146505874","https://openalex.org/W2147836450","https://openalex.org/W2168701969","https://openalex.org/W2175524623","https://openalex.org/W2180625639","https://openalex.org/W2234894755","https://openalex.org/W2242763250","https://openalex.org/W2255330917","https://openalex.org/W2269247374","https://openalex.org/W2292365150","https://openalex.org/W2305813686","https://openalex.org/W2309883476","https://openalex.org/W2326878087","https://openalex.org/W2399007860","https://openalex.org/W2399031492","https://openalex.org/W2401342417","https://openalex.org/W2412521257","https://openalex.org/W2413167169","https://openalex.org/W2414787191","https://openalex.org/W2416366082","https://openalex.org/W2416651642","https://openalex.org/W2416957726","https://openalex.org/W2417611977","https://openalex.org/W2471912039","https://openalex.org/W2473638526","https://openalex.org/W2474743289","https://openalex.org/W2562414697","https://openalex.org/W2993360096","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2272563341","https://openalex.org/W2066813211","https://openalex.org/W2091683518","https://openalex.org/W1876650137","https://openalex.org/W1828142674","https://openalex.org/W2325120158","https://openalex.org/W7097432024","https://openalex.org/W2055851285","https://openalex.org/W2180625639","https://openalex.org/W1938905957"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"increase":[2],"the":[3,18,112,118,166,179,246],"activity":[4],"of":[5,21,32,81,101,108,123,248],"cisplatin,":[6],"fluorouracil":[7],"(5-FU),":[8],"and":[9,16,23,57,73,103,131,160,174,209,227,238],"leucovorin":[10,58],"(PFL)":[11],"through":[12],"further":[13],"biochemical":[14],"modulation":[15],"study":[17],"pharmacologic":[19],"interaction":[20],"5-FU":[22,50,102,113,158,176,207,211,226,236],"interferon":[24],"alfa-2b":[25],"(IFN).":[26],"PATIENTS":[27],"AND":[28],"METHODS:":[29],"Escalating":[30],"doses":[31,219],"IFN":[33,124,161],"(0.5":[34],"to":[35,44,78,115,147],"4.0":[36],"x":[37,40,55,105,127,229],"10(6)":[38,106,128,230],"U/m2/d":[39,107,231],"6)":[41],"were":[42,86,133,185],"added":[43],"cisplatin":[45],"100":[46,59],"mg/m2,":[47],"continuous":[48],"infusion":[49],"800":[51,99],"or":[52],"640":[53,116,223],"mg/m2/d":[54,100,224],"5,":[56],"mg":[60],"orally":[61],"every":[62],"4":[63],"hours.":[64],"Forty-eight":[65],"previously":[66],"untreated":[67],"patients":[68,85,137,195],"with":[69,98,187,196,214],"locoregionally":[70],"advanced":[71],"head":[72],"neck":[74],"cancer":[75],"received":[76],"up":[77],"three":[79],"cycles":[80],"PFL-IFN.":[82],"RESULTS:":[83],"Twenty-one":[84],"treated":[87,138],"during":[88],"a":[89,150],"phase":[90],"I":[91],"cohort":[92],"study.":[93],"Dose-limiting":[94],"mucositis":[95],"was":[96,125,154],"seen":[97],"0.5":[104],"IFN.":[109,233],"After":[110],"decreasing":[111],"dose":[114,121],"mg/m2/d,":[117],"maximally":[119],"tolerated":[120],"(MTD)":[122],"2.0":[126,228],"U/m2/d.":[129],"Mucositis":[130],"myelosuppression":[132],"dose-limiting.":[134],"Of":[135],"34":[136],"at":[139,165],"this":[140,249],"MTD,":[141],"56%":[142],"(95%":[143],"confidence":[144],"interval,":[145],"39%":[146],"73%)":[148],"had":[149,199],"complete":[151],"remission.":[152],"There":[153],"no":[155],"correlation":[156],"between":[157],"clearance":[159,212],"dose.":[162],"Pharmacodynamic":[163],"analyses":[164],"MTD":[167],"showed":[168],"that":[169],"older":[170],"age,":[171,235],"female":[172],"sex,":[173],"higher":[175,206],"area":[177],"under":[178],"time":[180],"versus":[181],"concentration":[182],"curve":[183],"(AUC)":[184],"associated":[186],"lower":[188,210],"nadir":[189],"counts":[190],"and/or":[191],"increased":[192,201],"mucositis.":[193],"Seven":[194],"diabetes":[197,239],"mellitus":[198,240],"significantly":[200],"myelosuppression,":[202],"serum":[203],"creatinine,":[204],"hypocalcemia,":[205],"concentrations,":[208],"compared":[213],"nondiabetics.":[215],"CONCLUSION:":[216],"The":[217],"recommended":[218],"for":[220,225,232],"PFL-IFN":[221],"are":[222],"Sex,":[234],"AUC,":[237],"may":[241],"have":[242],"an":[243],"impact":[244],"on":[245],"pharmacodynamics":[247],"regimen.":[250]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}